Current Report · Items 5.02 · 8-K

Eikon Therapeutics, Inc.

EIKNNASDAQEQUITYCurrent

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements

Filed Aug 3, 2026Accepted Aug 3, 2026, 4:39 PM EDTCIK 1861123Accession 0001193125-26-330710

Company context

We are a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing important, innovative medicines to address serious unmet medical needs. We are led by world-renowned drug developers Dr. Roger M. Perlmutter, M.D., Ph.D., and Dr. Roy Baynes, M.D., Ph.D. Our vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. Our initial focus is oncology, where we are advancing a pipeline of drug candidates targeting areas of high unmet need in large indications. We believe our product candidates reflect strong scientific and clinical potential and could eventually become critical medicines in the treatment paradigm of various cancers.

Current securities

EIKNNASDAQ · EQUITY · Current

Recent company filings

Disclosure sections

Items 5.02

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 5.02Item 5.02 - Departure/Election of Directors

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Effective July 31, 2026, Leon Chen, Ph. D. and Joshua Wolfe resigned from the Board of Directors of Eikon Therapeutics, Inc. (the “Company”). Dr. Chen’s and Mr. Wolfe’s resignations were not because of a disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

Free Registration